姗姗来迟的Vir的新冠抗体终于也成功了！![[哭泣]](http://assets.imedao.com/ugc/images/face/emoji_09_cry.png?v=1 "[哭泣]"){kind=small}
在不住院的病人中使用VIR-7831可降低85%的住院和死亡率。
体外实验也表明，VIR-7831抗体对目前的英国，南非和巴西变异病毒都有效。
VIR-7831不但可以阻止病毒入侵健康的细胞，还可以帮助T细胞清除受感染的细胞。靶向的是病毒高度保守的区域，因此理论上还可以防住其它SARS类病毒，比如原SARS病毒。
The IDMC recommendation was based on an interim analysis of data from 583 patients enrolled in the COMET-ICE trial, which demonstrated an 85% (p=0.002) reduction in hospitalization or death in patients receiving VIR-7831 as monotherapy compared to placebo, the primary endpoint of the trial. VIR-7831 was well tolerated. As the trial remains ongoing and blinded with patients continuing to be followed for 24 weeks, additional results, including epidemiology and virology data, will be forthcoming once the trial is completed.
The dual-action design of VIR-7831 to both block viral entry into healthy cells and clear infected cells, as well as its high barrier to resistance, are key distinguishing characteristics.